Home › Rhabdomyosarcoma › Wisconsin
Rhabdomyosarcoma clinical trials in Wisconsin
4 studies for Rhabdomyosarcoma are looking for participants at sites in Wisconsin.
Cities in Wisconsin
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Medical College of Wisconsin, Milwaukee
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Nov 12, 2026 · NCT06541262Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- University of Wisconsin Carbone Cancer Center, Madison
RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 27, 2026 · NCT02508038Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
- Midwest Children's Hospital, Milwaukee
RecruitingPhase 1
12 Months – 20 Years · All sexes · Updated Oct 8, 2026 · NCT02013336A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Children's Hospital of Wisconsin, Milwaukee
RecruitingPhase 3
Up to age 50 · All sexes · Updated Aug 25, 2026 · NCT07466316From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.